BioCentury | Nov 10, 2014
Company News

F-star, F-star Beta deal

...F-star's F-star Biotechnology Ltd. subsidiary launched newco F-star Beta and granted it exclusive, worldwide rights to develop...
...Biotechnology is eligible for milestones and tiered royalties. F-star said specific terms are not disclosed. F-star Beta's...
...spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha. F-star Beta...
BioCentury | Nov 5, 2014
Company News

After BMS deal, F-star launches second newco

...F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop...
...immuno-oncology targets. F-star Biotechnology is eligible for milestones and tiered royalties. Specific terms are undisclosed. F-star Beta...
...ErbB2 ; neu), during the option period (see BioCentury, Nov. 3) . Haurum said F-star Beta's...
Items per page:
1 - 2 of 2
BioCentury | Nov 10, 2014
Company News

F-star, F-star Beta deal

...F-star's F-star Biotechnology Ltd. subsidiary launched newco F-star Beta and granted it exclusive, worldwide rights to develop...
...Biotechnology is eligible for milestones and tiered royalties. F-star said specific terms are not disclosed. F-star Beta's...
...spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha. F-star Beta...
BioCentury | Nov 5, 2014
Company News

After BMS deal, F-star launches second newco

...F-star Biotechnology Ltd. (Cambridge, U.K.) launched newco F-star Beta Ltd. (Cambridge, U.K.) and granted it licenses to develop...
...immuno-oncology targets. F-star Biotechnology is eligible for milestones and tiered royalties. Specific terms are undisclosed. F-star Beta...
...ErbB2 ; neu), during the option period (see BioCentury, Nov. 3) . Haurum said F-star Beta's...
Items per page:
1 - 2 of 2